INTRODUCTION {#s1}
============

Neck cancer metastasis with an unknown primary site (NCUP) presents in patients with neck lymph node involvement in the absence of an identifiable primary tumor \[[@R1]--[@R3]\]. The histopathology of NCUP consists of squamous cell carcinoma, adenocarcinoma, and other undifferentiated carcinomas \[[@R1]--[@R3]\]. The often-extensive diagnostic workup to identify the primary site can include physical examination, chest X-ray, endoscopy, biopsy, computed tomography (CT) or magnetic resonance imaging (MRI), and positron emission tomography (PET). Nonetheless, in approximately 2% to10 % of NCUP cases the primary site remains unidentified \[[@R1]--[@R12]\].

NCUP is thought to be potentially curable \[[@R2]\], but the data addressing the therapeutic protocols and outcomes of NCUP treatment are limited and controversial. The proposed treatment modalities include surgery alone, radiotherapy (RT) alone, and a combination of RT and surgery. Opinions on the field design for RT also vary. Some investigators have recommended involved-field irradiation, such as ipsilateral neck irradiation only \[[@R7], [@R11]--[@R14]\], while others suggest extended field irradiation, including prophylactic irradiation of potential head and neck mucosal sites and both sides of the neck \[[@R1], [@R4], [@R6], [@R15]\]. Differences in treatment strategy and patient selection have led to inconsistent results. Consequently, the reported 5-year overall survival (OS) rates for patients with NCUP range from 16% to 86%, and the local control rates range from 37% to 91%. The present meta-analysis was performed in an effort to identify the optimal treatment regimen for NCUP, focusing in particular on the optimal way to schedule RT.

RESULTS {#s2}
=======

Description of selected studies and quality assessment {#s2_1}
------------------------------------------------------

A total of 787 articles were identified, of which 33 articles qualified for inclusion. The flow diagram for study selection is shown in Figure [1](#F1){ref-type="fig"}. The characteristics of the included studies are summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Although methods for managing missing data are not adequately described in some studies, none of the included studies had a NOS \< 6, which suggests all were of high quality.

![Flow diagram of studies identification and selection](oncotarget-07-78736-g001){#F1}

###### Baseline characteristics of the included studies

  Study              Patients No.   Age(year)          Studyperiod   Country                Follow up         Gender(Male/Female)   Design   Quality score   Histology   [\*](#tfn_001){ref-type="table-fn"}Nodal stage (NX-1/N2-3)   Nodal level (I-II/III-IV)
  ------------------ -------------- ------------------ ------------- ---------------------- ----------------- --------------------- -------- --------------- ----------- ------------------------------------------------------------ ---------------------------
  1973Jesse          184            NA                 1948--1968    USA                    \> 3Y             NA                    R        7               1,3         63/121                                                       162/48
  1975Fried          43             NA                 1958--1969    USA                    NA                2:1                   R        6               1,2,3       NA                                                           NA
  1979Nordstrom      39             60(13--88)         1960--1973    USA                    NA                40/11                 R        6               1,2,3       8/43                                                         NA
  1981Leipzig        32             51(22--76)         1969--1977    USA                    NA                2:1                   R        7               1           14/18                                                        NA
  1986Carlson        93             NA                 1968--1980    USA                    \> 3Y             70/23                 R        7               1,2,3       41/52                                                        61/32
  1987Bataini        138            57.5(15--82)       1960--1980    USA                    \> 5Y             117/21                R        8               1           45/93                                                        NA
  1990Glynne         58             61(12--85)         1954--1986    UK                     35(4--300)M       53/34                 R        7               1,3         11/76                                                        NA
  1990Harper         69             58.5(26--91)       1964--1986    Australia              \> 2Y             58/11                 R        8               1           18/51                                                        NA
  1990Marcial        72             58.5(24--85)       1965--1987    USA                    NA                50/22                 R        6               1,3         12/60                                                        35/37
  1995Weir           144            60(28--90)         1970--1986    Canada                 3.5(4--15)Y       110/34                R        8               1,2,3       79/65                                                        NA
  1997Reddy          52             59(30--79)         1974--1989    USA                    \> 5Y             50/2                  R        9               1           9/43                                                         NA
  1997 Sinnathamby   67             62(29--84)         1983--1992    Australia              7M-7Y             51/18                 R        8               1,3         9/60                                                         NA
  1997van der        44             66(20--86)         1974--1991    Netherlands            7.3Y(2--18.8)     35/9                  R        7               1,2,3       4/40                                                         NA
  1998Colletier      136            59(25--83)         1968--1992    Canada                 58(3--267)M       103/33                R        7               1           41/95                                                        104/32
  1998Strojan        56             56(33--81)         1975--1994    Slovenia               8.6(1.6--17.8)Y   50/6                  R        8               1           6/50                                                         39/17
  2000Grau           352            62(18--92)         1975--1995    Denmark                5Y                248/104               R        7               1,3         48/225                                                       277/0
  2000McMahon        34             67(45--84)         1987--1998    Australia              2.7(0.9--6.7)Y    28/10                 R        8               1           6/32                                                         31/7
  2002Tong           45             57(29--91)         1988--1998    Hong Kong              79M(27--110)      37/8                  R        7               1,2,3       7/38                                                         20/25
  2002Yalin          114            48(18--78)         1976--1988    China                  NA                NA                    R        7               1,2,3       33/81                                                        NA
  2002Zuur           14             62.6(34.7--82.8)   1975--1999    Netherlands            2--67M            8/8                   R        7               1,2         2/13                                                         3/12
  2006Boscolo        79             64.7±9.3           1980--2001    Italy                  15Y               69/13                 R        8               1           10/62                                                        60/12
  2007Aslani         61             57(37--87)         1987--2002    Canada                 31(7--168)M       49/12                 R        7               1,3         16/45                                                        53/8
  2007Beldi          113            59.3(23--88)       1980--2004    Italy                  NA                93/20                 R        7               1,2,3       21/92                                                        83/30
  2008Huang          31             63.3(36--84)       1980--2000    Taiwan                 NA                35/13                 R        8               1           3/45                                                         39/9
  2009Ligey          95             59(38--80)         1990--2007    France                 3.3Y(5M-11.7Y)    84/11                 R        7               1,3         25/70                                                        77/18
  2009Lu             60             53(23--81)         1989--2003    China                  58(10--135)M      46/14                 R        8               1           10/50                                                        44/16
  2009Rodel          58             55(37--77)         1980--2004    Germany                83.5M(24--162)    58/10                 R        7               1,2,3       9/49                                                         55/3
  2011Chen           60             60(42--90)         2001--2009    USA                    30M(3--90)        39/21                 R        8               1           5/55                                                         51/9
  2011Wallace        179            61(26--89)         1990--2006    USA                    4.2Y(0.2--25.4)   157/22                R        8               1           18/161                                                       NA
  2012Fakhrian       65             60(39--90)         1988--2009    Germany                64(3--219)M       52/13                 R        9               1,3         14/51                                                        46/19
  2012Perkins        46             60(40--82)         1989--2008    USA                    4.6Y(7M-18Y)      NA                    R        9               1           3/43                                                         NA
  2014Demiroz        41             53(38-72)          1994-2009     USA                    11-126M           37/4                  R        9               1           4/37                                                         33/8
  2015Straetmans     46             NA                 1997-2010     Netherlands, Germany   NA                44/7                  R        8               1           4/42                                                         NA

According to UICC/AJCC staging system. R = retrospective; Y = year; M = month; NA = Not available;

1 = squamous cell carcinoma; 2 = adenocarcinoma; 3 = undifferentiated carcinoma

###### Baseline characteristics of the treatments of the included studies

  Study             Patients No.   Chemotherapy   Radiotherapy   Surgery                       
  ----------------- -------------- -------------- -------------- ----------------------- ----- --------
  1973Jesse         184            0              80             BN+PPTS,IN+PPTS,BN,IN   132   ND,E
  1975Fried         43             0              43             BN+PPTS,IN+PPTS,BN,IN   16    ND
  1979Nordstrom     39             0              39             BN+PPTS,IN+PPTS,IN      34    ND
  1981Leipzig       32             0              24             BN+PPTS,IN+PPTS,BN,IN   24    ND
  1986Carlson       93             0              93             BN+PPTS,IN+PPTS,BN,IN   70    ND,E
  1987Bataini       138            0              138            BN+PPTS,BN,IN           48    ND
  1990Glynne        58             1              58             BN+PPTS,IN+PPTS,BN,IN   6     ND
  1990Harper        69             0              69             BN+PPTS,IN+PPTS,BN,IN   30    ND
  1990Marcial       72             0              72             BN+PPTS,IN+PPTS,BN,IN   31    ND,E
  1995Weir          144            0              144            BN+PPTS,IN+PPTS,BN,IN   71    E
  1997Reddy         52             0              52             BN+PPTS,IN              39    ND,E
  1997Sinnathamby   67             0              63             BN,IN                   44    ND,E
  1997van der       44             0              44             BN+PPTS,IN+PPTS,BN,IN   31    ND,E
  1998Colletier     136            0              136            BN+PPTS,IN+PPTS,BN,IN   136   ND,E
  1998Strojan       56             0              56             BN+PPTS,IN+PPTS,IN      56    ND,E
  2000Grau          352            0              250            BN+PPTS,IN              169   ND,E
  2000McMahon       34             0              34             BN+PPTS,IN              34    ND
  2002Tong          45             8              36             BN+PPTS                 13    ND,E
  2002Yalin         114            39             76             BN+PPTS,IN+PPTS,BN,IN   24    ND,E,T
  2002Zuur          14             0              14             BN+PPTS,IN+PPTS,BN,IN   7     ND
  2006Boscolo       79             0              79             BN+PPTS,IN              50    ND
  2007Aslani        61             0              61             BN+PPTS,BN,IN           29    ND,E
  2007Beldi         113            21             113            BN+PPTS,BN,IN           99    ND,E
  2008Huang         31             16             31             BN+PPTS                 30    ND
  2009Ligey         95             43             95             BN+PPTS,IN+PPTS,BN,IN   79    ND
  2009Lu            60             14             60             BN+PPTS,BN,IN           9     E
  2009Rodel         58             22             50             BN+PPTS,IN              53    ND
  2011Chen          60             32             60             BN+PPTS,IN+PPTS,IN      45    ND,E
  2011Wallace       179            13             179            BN+PPTS,IN+PPTS,IN      109   ND
  2012Fakhrian      65             19             65             BN+PPTS,IN              51    ND,E
  2012Perkins       46             14             46             BN+PPTS,IN+PPTS,BN,IN   40    ND,E
  2014Demiroz       41             25             41             BN+PPTS,BN,IN           22    ND
  2015Straetmans    51             8              48             BN+PPTS,BN,IN           51    ND

Abbreviations: BN = Bilateral neck; IN = Ipsilateral neck; PPTS = Potential primary tumor sites.

Neck dissection = ND, Excision = E, Thyroidectomy = T.

RT alone versus RT combined with surgery {#s2_2}
----------------------------------------

Eighteen studies \[[@R2], [@R5], [@R9], [@R10], [@R16]--[@R29]\], with a total of 1582 patients, were included in this analysis. Compared to RT alone, the combination of RT and surgery significantly improved 5-year OS (RR = 0.66, 95% CI 0.52--0.83, *p* = 0.0004) (Figure [2A](#F2){ref-type="fig"}). The benefit to 5-year DFS showed a similar trend (RR = 0.81, 95% CI 0.62--1.07, *p* = 0.13) (Figure [2B](#F2){ref-type="fig"}), though this did not reach statistical significance. Additionally, surgery in combination with RT was associated with a significantly decreased NR rate (RR = 0.74, 95% CI 0.59--0.72, *p* = 0.008) (Figure [2D](#F2){ref-type="fig"}) and an increased CR rate (RR = 0.37, 95% CI 0.21--0.64, *p* = 0.0003) (Figure [2C](#F2){ref-type="fig"}).

![Meta-analysis of (**A**) 5-year OS, (**B**) 5-year DFS,(**C**) CR, (**D**) NR between RT alone and RT combined with surgery. S, Surgery; RT, Radiotherapy.](oncotarget-07-78736-g002){#F2}

Ipsilateral versus bilateral neck irradiation {#s2_3}
---------------------------------------------

Sixteen studies \[[@R1], [@R3]--[@R7], [@R11]--[@R15], [@R23], [@R20]--[@R33]\] with a total of 1449 patients, meeting the inclusion criteria were selected for this analysis (Table B). Bilateral neck irradiation contributed to better local control with a lower NR rate (RR = 0.61, 95% CI 0.41--0.91, *p* = 0.01) (Figure [3A](#F3){ref-type="fig"}) and PTE rate (RR = 0.44, 95% CI 0.26--0.77, *p* = 0.004) (Figure [3B](#F3){ref-type="fig"}). This was especially true for contralateral neck control (RR = 0.30, 95% CI 0.15--0.59, *p* \< 0.0005) (Figure [3C](#F3){ref-type="fig"}). Moreover, when compared to ipsilateral irradiation, bilateral neck irradiation showed a potential survival advantage with greater 5-year OS (RR = 0.86, 95% CI 0.61--1.22, *p* = 0.40) (Figure [3D](#F3){ref-type="fig"}) and 5-year DFS (RR = 0.81, 95% CI 0.64--1.03, *p* = 0.09) (Figure [3E](#F3){ref-type="fig"}), although this benefit was not statistically significant.

![Meta-analysis of (**A**) NR, (**B**) PTE, (**C**) CNR, (**D**) 5-year OS, and (**E**) 5-year DFS between ipsilateral neck irradiation and bilateral neck irradiation. BN, Bilateral neck; IN, Ipsilateral neck; RT, Radiotherapy.](oncotarget-07-78736-g003){#F3}

Neck-only versus neck plus PPTS irradiation {#s2_4}
-------------------------------------------

Fifteen studies \[[@R1]--[@R8], [@R11]--[@R13], [@R15], [@R22], [@R30], [@R33]\], with a total of 1347 patients, fulfilled the inclusion criteria and were included in this analysis. As compared to neck-only irradiation, superior 5-year DFS (RR 0.75, 95% CI 0.61--0.92, *p* = 0.005) (Figure [4A](#F4){ref-type="fig"}) and a trend toward increased 5-year OS (RR = 0.70, 95% CI 0.48--1.01, *p* = 0.06) (Figure [4B](#F4){ref-type="fig"}) were observed in patients treated with neck and PPTS irradiation. In addition, neck and PPTS irradiation had a significant advantage for reducing NR rate (RR = 0.72, 95% CI 0.56--0.92, *p* = 0.009) (Figure [4C](#F4){ref-type="fig"}), CNR rate (RR = 0.23, 95% CI 0.12--0.45, *p* \< 0.0001) (Figure [4D](#F4){ref-type="fig"}) and PTE rate (RR = 0.59, 95% CI 0.39--0.89, *p* = 0.01) (Figure [4E](#F4){ref-type="fig"}).

![Meta-analysis of (**A**) NR, (**B**) PTE, (**C**) CNR, (**D**) 5-year OS, and (**E**) 5-year DFS between neck only irradiation and neck plus potential primary tumour sites irradiation. N, Neck only; N+PPTS, Neck plus potential primary mucosa sites; RT, Radiotherapy.](oncotarget-07-78736-g004){#F4}

Toxic effects of different radiotherapeutic regimens {#s2_5}
----------------------------------------------------

Only two of the included studies \[[@R11], [@R15]\] compared toxicities between ipsilateral neck irradiation and bilateral neck plus PPTS irradiation, and the toxicity data could only be assessed for severe acute toxicity and xerostomia. We found there was an increased risk of severe acute toxicity (RR = 1.91, 95% CI 1.26--2.88, *p* = 0.002) ([Supplementary Figure S1A](#SD1){ref-type="supplementary-material"}) and xerostomia (RR = 6.82, 95% CI 0.96--48.55, *p* = 0.06) ([Supplementary Figure S1B](#SD1){ref-type="supplementary-material"}) in the group with bilateral neck and PPTS irradiation.

DISCUSSION {#s3}
==========

Optimal treatment for patients with NCUP remains uncertain. The incidence of NCUP is about 3 cases per 1,000,000 per year. Its rarity makes randomized and prospective studies unavailable, and leaves clinicians with only small retrospective studies for clinical decision making. To the best of our knowledge, this study is the first meta-analysis with a focus on comparing the therapeutic efficacies of different treatment regimens, and on providing a higher level of evidence for optimizing the RT schedule in NCUP.

Some studies held that surgery plus RT resulted in a higher probability of cure \[[@R2], [@R5], [@R9], [@R27], [@R28]\], while others reported that the outcome of surgery plus RT were similar to those of definitive RT alone, but with a higher risk of severe complications \[[@R19], [@R25], [@R29]\]. We therefore first performed a comparison of RT alone with RT plus surgery. The pooled analysis demonstrated that RT plus surgery was associated with a greater 5-year OS rate than RT alone. Moreover, there was a beneficial trend toward a higher 5-year DFS, though the effect was not significant. The higher CR rate and lower NR rate is also consistent with a survival benefit from the combination of surgery and RT.

For neck-irradiation settings, the current guidelines suggest treating the involved lymph node field \[[@R34]\]. However, some reports indicate that patients administered RT to the bilateral neck nodes appeared to have greater local control and higher survival rates than those who received only ipsilateral irradiation \[[@R1], [@R4], [@R6], [@R15]\]. In the present pooled analysis, significantly less contralateral cervical recurrence or emergence of a primary tumor was noted in patients receiving bilateral irradiation, and there was trend toward increased 5-year OS and DFS. These findings suggest that current guidelines recommending the involved lymph node field as the standard RT schedule may need to be re-evaluated for the NCUP setting.

As to the value of irradiation of the PPTS, although current guidelines recommend it as routine consideration for inclusion in the target volume \[[@R34]\], conclusions drawn from currently available evidence are controversial. Some studies have shown a higher 5-year OS rate and better regional control with addition of irradiation of potential head and neck mucosal sites of cancer growth \[[@R1], [@R4]--[@R6], [@R8], [@R13], [@R15]\], whereas, other trials observed that mucosal irradiation reduced both the emergence of primary tumors and regional recurrence, but did not affect OS \[[@R3], [@R7], [@R12]\]. In the pooled analysis of all these trials, not only was an advantage for regional control validated, so was a survival benefit in patients treated with irradiation of the neck and PPTS.

We also evaluated the toxic effects of different RT regimens. Because the data were limited, we only assessed severe acute toxicities and xerostomia. We found a significantly higher risk of these adverse events in the RT to the bilateral neck plus PPTS group. However, it is believed that these severe acute toxicities are clinically manageable, and xerostomia could be minimized by application of intensity modulated RT (IMRT) \[[@R11], [@R15]\].

There were several limitations to this study. First, all the included studies were retrospective and the sample groups were small. There was not sufficient data to perform subgroup analyses based on lymph node levels, lymph node stages, histological types, sequence of surgery and RT, or radiation dosage. Second, these studies were performed over a long time-span. Consequently, the techniques for delivering RT were varied, and precision RT techniques, such as 3-D conformal RT and IMRT, were not yet broadly applied. This could result in an underestimation of the actuarial effect of RT. To address these issues, future multicenter RCTs are needed.

MATERIALS AND METHODS {#s4}
=====================

Literature search and selection {#s4_1}
-------------------------------

Two authors (X.M.L. and X.X.Z.) independently carried out systematic literature searches of EMBASE, Cochrane, Pubmed and Web of Science before September 25, 2015. The following terms were used: occult primary, unknown primary, neck lymph node, cervical lymph node, metastatic, metastases, cancer, neoplasm, tumor, carcinoma, radiotherapy, irradiation, radiation.

Studies meeting the following selection criteria were included. (1) Study population: patients with cervical lymph node metastases from unknown primary sites, and with no cancer history. (2) Study design: comparative studies comparing RT alone with a combination of RT and surgery (radical neck dissection, selective neck dissection, or excisional biopsy); comparing ipsilateral irradiation with bilateral irradiation; or comparing neck-only irradiation with neck and potential primary tumor site (PPTS) (nasopharynx, oropharynx, larynx, and/or hypopharynx) irradiation. (3) Language: English. (4) Studies with available data on at least one of the pre-specified endpoints: 5-year OS, 5-year disease free survival (DFS), neck recurrence (NR), complete response (CR), primary tumor emergence (PTE), ipsilateral neck recurrence (INR), contralateral neck recurrence (CNR), severe acute toxicity (RTOG grade≥3) and xerostomia. Editorials, letters to the editor, and review articles were excluded (Figure [1](#F1){ref-type="fig"}).

Data extraction {#s4_2}
---------------

The following items were extracted independently by the two authors (X.M.L. and D.H.L.) from the published articles: year of publication, first author, country, study period, demographic and clinical information on the study patients (age, gender, histology, N stage, N level), schedule of treatment, number of patients, outcome results, and follow-up. Any disagreement was resolved through further discussion and including a third author.

Quality assessment {#s4_3}
------------------

The quality of each study was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS), which considers of the following factors: patient selection, comparability of the study groups, and assessment of outcome \[[@R35], [@R36]\]. Each study was assigned a score of between 0 and 9. Any discrepancies were resolved by discussion. Studies with a score of \> 5 were regarded as high-quality studies.

Statistical analysis {#s4_4}
--------------------

All the meta-analyses were performed using Review Manager 5.2 (Cochrane Collaboration, Oxford, UK). Each pre-specified outcome was measured in terms of the risk ratios (RRs) \[[@R36]\] and its 95% confidence intervals (CIs). Two-sided values of *P* \< 0.05 were considered statistically significant. Heterogeneity among studies was determined by the Chi-square test and an inconsistency (I^2^) statistic of forest plots. I^2^ \> 40% or *P* \< 0.10 indicated significant heterogeneity \[[@R37]\]. If there was significant heterogeneity among studies, a random-effects model was used. Otherwise, a fixed-effects model was used \[[@R37], [@R38]\].

CONCLUSIONS {#s5}
===========

This study suggests that, in patients with NCUP, surgery combined with RT to bilateral neck and PPTS may be the preferable treatment option, as it is associated with improvements in survival and regional control. On the other hand, this recommendation is not based on randomized trials, and one must be alert for severe acute toxicity and xerostomia.
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